Our results demonstrated that CD8-predominant AITL has an immunosuppressive TME, indicating that CD8-predominant AITL is at a later stage of tumor development and thus has significantly inferior survival compared to common AITLs. The gene discussed is CD8A; the disease is neoplasm.